Sun Pharmaceutical Industries, Inc.
sunpharma.comLive pipeline data from ClinicalTrials.gov, refreshed daily.
Total trials
79
Active
4
Phase 3
15
Total enrollment
40,476
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Reformulated Levulan Kerastick containing aminolevulinic acid hydrochloride (ALA HCl), 20% | — | — | — | — | — | 2 | |
| CTP-543 | — | — | — | — | — | 2 | |
| Deuruxolitinib | — | — | — | — | — | 1 |
Next readouts
- 2027-01
- 2027-01
- 2027-05
- 2028-05
Top conditions
- Acne Vulgaris22
- Plaque Psoriasis8
- Tinea Pedis7
- Psoriasis5
- Actinic Keratosis5
- Atopic Dermatitis4
- Pediculosis4
- Scalp Psoriasis4
Frequently asked questions about Sun Pharmaceutical Industries, Inc.
- How many clinical trials does Sun Pharmaceutical Industries, Inc. have on ClinicalTrials.gov?
- Sun Pharmaceutical Industries, Inc. is listed as the lead sponsor on 79 clinical trials in ClinicalTrials.gov, 4 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Sun Pharmaceutical Industries, Inc.'s trials are in Phase 3?
- 15 of Sun Pharmaceutical Industries, Inc.'s trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Sun Pharmaceutical Industries, Inc. focus on?
- Sun Pharmaceutical Industries, Inc.'s most-studied conditions on ClinicalTrials.gov are Acne Vulgaris, Plaque Psoriasis, Tinea Pedis, Psoriasis, Actinic Keratosis.
- When are Sun Pharmaceutical Industries, Inc.'s next clinical trial readouts?
- Sun Pharmaceutical Industries, Inc. has 4 upcoming primary-completion readouts tracked here; the soonest is “Study of Reformulated Levulan Kerastick Plus PDT for Actinic Keratosis on Face and Scalp”, expected around 2027-01.